Re: Laboratory safety evaluation of bedinvetmab, a canine anti-nerve growth factor monoclonal antibody, in dogs

被引：3
|
作者：
Farrell, Mike [1 ]
Adams, Rob [2 ]
von Pfeil, Dirsko J. F. [3 ]
机构：
[1] Vetlessons, 25 James Carter Rd, Bury St Edmunds IP28 7DE, England
[2] Paragon Vet Referrals, Red Hall Crescent, Wakefield WF1 2DF, England
[3] PLLC, Small Anim Surg Locum, Dallas, TX USA
来源：
VETERINARY JOURNAL | 2024年 / 305卷
关键词：
Bedinvetmab; Librela; Rapidly progressive osteoarthritis; RPOA;
D O I：
10.1016/j.tvjl.2024.106104
中图分类号：
S85 [动物医学（兽医学）];
学科分类号：
0906 ;
摘要：
We are writing to express our interest in the article entitled "Laboratory safety evaluation of bedinvetmab, a canine anti -nerve growth factor monoclonal antibody, in dogs", published in the October, 2021 issue of The Veterinary Journal , Volume 276, 105733, by Krautmann and others.
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Efficacy of Anti-Nerve Growth Factor Therapy for Discogenic Neck Pain in Rats
    Sainoh, Takeshi
    Sakuma, Yoshihiro
    Miyagi, Masayuki
    Orita, Sumihisa
    Yamauchi, Kazuyo
    Inoue, Gen
    Kamoda, Hiroto
    Ishikawa, Tetsuhiro
    Suzuki, Miyako
    Kubota, Go
    Oikawa, Yasuhiro
    Inage, Kazuhide
    Sato, Jun
    Nakamura, Junichi
    Aoki, Yasuchika
    Takaso, Masashi
    Toyone, Tomoaki
    Takahashi, Kazuhisa
    Ohtori, Seiji
    SPINE, 2014, 39 (13) : E757 - E762
  • [42] Biologically active anti-nerve growth factor antibodies in commercial intravenous gammaglobulin
    Warrington, Richard J.
    Lewis, Keith E.
    JOURNAL OF AUTOIMMUNITY, 2007, 28 (01) : 24 - 29
  • [43] MEMORY IMPAIRMENT AND MORPHOLOGICAL-CHANGES IN RATS INDUCED BY ACTIVE FRAGMENT OF ANTI-NERVE GROWTH FACTOR-ANTIBODY
    NABESHIMA, T
    OGAWA, S
    ISHIMARU, H
    KAMEYAMA, T
    FUKUTA, T
    TAKEUCHI, R
    HAYASHI, K
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1991, 175 (01) : 215 - 219
  • [44] POTENTIAL MECHANISMS FOR HYPOALGESIA INDUCED BY ANTI-NERVE GROWTH FACTOR IMMUNOGLOBULIN ARE IDENTIFIED USING AUTOIMMUNE NERVE GROWTH FACTOR DEPRIVATION
    Hoffman, E. M.
    Zhang, Z.
    Anderson, M. B.
    Schechter, R.
    Miller, K. E.
    NEUROSCIENCE, 2011, 193 : 452 - 465
  • [45] Efficacy, safety, and tolerability of fulranumab, an anti-nerve growth factor antibody, in the treatment of patients with moderate to severe osteoarthritis pain (vol 154, pg 1910, 2013)
    Sanga, Panna
    Katz, Nathaniel
    Polverejan, Elena
    Wang, Steven
    Kelly, Kathleen M.
    Haeussler, Juergen
    Thipphawong, John
    PAIN, 2014, 155 (01) : 204 - 204
  • [46] Measuring the effect of the anti-nerve growth factor antibodies bedinvetmab and frunevetmab on quality of life in dogs and cats with osteoarthritis using a validated health-related quality of life outcome measure: an observational real-world study
    Reid, Jacqueline
    Gildea, Edwina
    Davies, Vinny
    Thompson, Jill
    Scott, Marian
    FRONTIERS IN VETERINARY SCIENCE, 2024, 11
  • [47] Anti-nerve growth factor (anti-NGF) monoclonal antibody increases lipopolysaccharide (LPS)-induced transforming growth factor-beta 1 (TGF beta 1) release from mouse urinary bladder.
    Saban, R
    HaakFrendscho, M
    MentoneSaban, DR
    Bjorling, DE
    FASEB JOURNAL, 1996, 10 (03): : 967 - 967
  • [48] Effect of anti-nerve growth factor on early and late airway responses in allergic rats
    Glaab, T
    Hoymann, HG
    Hecht, M
    Korolewitz, R
    Tschernig, T
    Hohlfeld, JM
    Krug, N
    Braun, A
    ALLERGY, 2003, 58 (09) : 900 - 904
  • [49] CLINICAL EFFICACY AND SAFETY OF MONOCLONAL ANTIBODY AGAINST NERVE GROWTH FACTOR AND FIBROBLAST GROWTH FACTOR-18 THERAPY OF OSTEOARTHRITIS
    Pallav, M.
    Zaripova, L.
    Tazhibaeva, D.
    Kabdualieva, N.
    ANNALS OF THE RHEUMATIC DISEASES, 2022, 81 : 892 - 892
  • [50] Pain Therapy using Anti-nerve growth factor antibodies? Pain Research in a Dilemma
    Schaible, Hans-Georg
    SCHMERZ, 2021, 35 (05): : 301 - 303
12345